 Rocket Pharmaceuticals Inc NASDAQ: RCKT has announced positive data from its Fanconi Anemia FA, Leukocyte Adhesion Deficiency-I LAD-I, and Pyruvate Kinase Deficiency PKD gene therapy programs. Data were presented at the American Society of Gene and Cell Therapy Annual Meeting. 